|Age:||18 years or older|
|Keywords:||VEnous Thromboembolism, anticoagulants, blood thinners, blood clot|
|Type:||Drug study, Phase 3|
If eligible, you will be randomly assigned (like drawing straws or flipping a coin) to either receive warfarin (target INR of 2-3), apixaban (2.5mg twice daily) or rivaroxaban (20mg daily). Participants should start on the assigned study drug within one week of randomization. Participants on once daily medications will have flexibility in determining the daily dosing timing. You will receive a prescription for the medication you are assigned to.
The following test and procedures will be performed for this study: • At the Screening/Randomization visit (Visit 1) o Review and sign the Informed Consent Document o Physical exam including vital signs o A review of medication(s) you have taken and are currently taking to treat your DVT/PE
• At the Follow-up phone Visits (Month 1, Month 6 and Month 12) o You will be contacted by the Duke Clinical Research Institute (DCRI) Call Center to talk with you about the following: A review of medication(s) you have taken and are currently taking since the previous visit Review of information on specific events you may have experienced
• INR level checks • Your INR level will be routinely checked as part of standard care (weekly or monthly) based on your study doctor’s assessment of how stable you are.
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.